ReviewChemical science2026
Copper-based single-atom nanozymes: from fundamental insights to biomedical applications.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multifunctional Vitamin BAntioxidants (Basel, Switzerland) · 2026Article
- Copper-Doped Prussian Blue Nanozymes With Hyaluronic Acid-Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Beyond antibiotics: engineered metal nanozymes for resistance-evading antibacterial therapy.Journal of nanobiotechnology · 2026Review
- Metal-Functionalized Nanozymes in Antibacterial Wound Management: Recent Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper-based single-atom nanozymes (Cu SAzymes) have emerged as a revolutionary class of enzyme mimics, distinguished by their maximized atom utilization efficiency, well-defined active sites, and superior catalytic performance. This review provides a comprehensive overview of the latest advances in Cu SAzymes, systematically outlining their diverse enzyme-like activities, the atomic-level strategies for modulating their catalytic behavior, and their burgeoning applications in biosensing, antibacterial and anticancer therapy, and anti-inflammatory treatment. We emphasize the critical structure-activity relationships that govern their multi-enzyme capabilities and highlight innovative designs that enable synergistic and stimulus-responsive therapies. By establishing a framework that links atomic structure to enzyme-mimicking function and, ultimately, to advanced therapeutic utility, this review not only summarizes the current state of the art but also outlines prevailing challenges and future directions, underscoring the significant potential of Cu SAzymes to drive interdisciplinary innovations in nanobiotechnology and precision medicine.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.